Jump Financial LLC Makes New Investment in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Jump Financial LLC purchased a new stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 51,415 shares of the company's stock, valued at approximately $505,000. Jump Financial LLC owned about 0.09% of Ginkgo Bioworks at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. SBI Securities Co. Ltd. purchased a new stake in shares of Ginkgo Bioworks during the fourth quarter valued at approximately $29,000. KBC Group NV bought a new stake in shares of Ginkgo Bioworks in the fourth quarter valued at $31,000. KLP Kapitalforvaltning AS purchased a new position in shares of Ginkgo Bioworks during the 4th quarter valued at $46,000. Bank of New York Mellon Corp lifted its position in shares of Ginkgo Bioworks by 48.2% during the 4th quarter. Bank of New York Mellon Corp now owns 23,061 shares of the company's stock valued at $226,000 after buying an additional 7,503 shares during the last quarter. Finally, Monaco Asset Management SAM grew its stake in shares of Ginkgo Bioworks by 3.9% during the 4th quarter. Monaco Asset Management SAM now owns 384,664 shares of the company's stock worth $3,777,000 after acquiring an additional 14,539 shares during the period. 78.63% of the stock is owned by hedge funds and other institutional investors.

Ginkgo Bioworks Price Performance

NYSE:DNA traded down $0.01 on Wednesday, reaching $7.37. 1,235,752 shares of the company's stock were exchanged, compared to its average volume of 1,483,716. The firm has a market cap of $427.71 million, a price-to-earnings ratio of -0.56 and a beta of 1.34. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.00 and a 52 week high of $41.20. The stock has a fifty day simple moving average of $7.38 and a 200-day simple moving average of $9.13.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.